King Pharm.'s Advertising Suit Against Rival Hits Snag

Law360, New York (December 11, 2009, 2:16 PM EST) -- Saying lost profits and market share King Pharmaceuticals Inc. sustained following the introduction of Zymogenetics Inc.'s competing blood-clotter are not necessarily the result of unfair competition, a federal judge has denied three of King's preliminary injunction motions while noting that Zymogenetics already has voluntarily provided much of the relief requested.

Judge Dennis Inman of the U.S. District Court for the Eastern District of Tennessee tossed the motions Thursday, ruling that King had not sufficiently proven that it would be irreparably harmed absent the injunctions and that...
To view the full article, register now.